The cystatin C assay market is set for significant expansion as the global healthcare landscape shifts toward early detection ...

Nov 2024 - PYC Therapeutics (ASX:PYC) has announced plans to advance its investigational drug candidate, PYC-003, into human ...

Unicycive Therapeutics has positioned itself as an innovator in the CKD treatment space, with its lead product candidate, Oxylanthanum Carbonate (OLC), at the forefront of its development pipeline.

As the company progresses through key regulatory milestones and clinical trials, investors and industry observers are closely watching its potential to disrupt the hyperphosphatemia treatment ...

alkali supplementation and bisphosphonates but treatment must be individualized to account for comorbid conditions such as chronic kidney disease (CKD). Treatment options to prevent recurrence of ...